Compare Amcor PLC (AMCR) vs Becton Dickinson and Co (BDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amcor PLC vs Becton Dickinson and Co — how do they compare? Amcor PLC trades at $46.77 (market cap $21.92B), while Becton Dickinson and Co trades at $180.59 (market cap $49.41B). The key difference: Becton Dickinson and Co is far larger — about 2.3× Amcor PLC's market cap, and Amcor PLC pays the higher dividend (5.49%). Which is the better fit depends on your goals.
| AMCR | BDX | |
|---|---|---|
Market Cap | $21.92B | $49.41B |
Sector | Basic Materials | Health |
52-Week High | $50.58 | $185.39 |
52-Week Low | $36.69 | $138.62 |
Enterprise Value | $37.03B | $65.51B |
Dividend Yield | 5.49% | 2.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMCR trades at $46.85, down 0.55% today, with a bullish technical outlook supported by moving averages and strong earnings beats in the last four quarters. The company reported Q2 2026 EPS of $1.23, exceeding estimates, and maintains a 64% analyst buy rating with a $47.00 consensus target. Recent news highlights expansion in China and strong Q4 results, though net income margin declined to 3.06% in 2025.
The stock presents a balanced opportunity with solid earnings performance and analyst support, but risks include elevated P/E of 38.07, margin pressure, and high debt levels. Upside is capped near-term by technical resistance at $48, while support lies at $46.
BDX trades at $179.63, up 1.57% with a bullish technical outlook supported by moving averages. The company reported strong Q3 2026 earnings, beating estimates with $3.23 EPS versus $3.14 expected, and raised full-year guidance. Revenue growth remains steady at 4.4% FX-neutral, though margins face pressure from tariffs. Analysts maintain a mixed consensus with 47% buy ratings and a $183 price target, suggesting modest upside from current levels.
The stock presents a balanced opportunity with solid fundamentals and dividend stability, but faces headwinds from margin compression and competitive pressures. Near-term catalysts include continued execution on growth initiatives, while risks include tariff impacts and healthcare regulatory changes. The current valuation at 31.39 P/E appears fair given growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amcor PLC
Amcor is a global plastics packaging behemoth, with global sales of USD 14.5 billion in fiscal 2022 following the acquisition of Bemis in 2019. Amcor's operations span over 40 countries globally and include significant emerging-market exposure equating to circa 20% of sales. Amcor's capabilities span flexible and rigid plastic packaging, which sell into defensive food, beverage, healthcare, household, and personal-care end markets.
Read more on AMCR →About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →
